



A32964-072874.0132

#23
M. 89
3/25/03

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Achenbach
 Serial No. : 09/463,851 Examiner: Patten, P.
 Filed : June 5, 2000 Group Art Unit: 1651
 For : PHARMACEUTICAL COMPOUNDS ISOLATED FROM
 ARISTOLOCHIA TALISCANA

DECLARATION OF PETER HYLANDS
UNDER 37 C.F.R. 1.132

I hereby certify that this paper is being deposited with the United States
 Postal Service as first class mail in an envelope addressed to: Assistant Commissioner
 for Patents, Washington, D.C. 20231

March 10, 2003

Date of Deposit

Carmella L. Stephens
 Attorney Name

Carmella L. Stephens
 Signature

41-328
 Registration No.

March 10, 2003
 Date of Signature

Assistant Commissioner for Patents
 Washington, D.C. 20231

Sir:

Laundry Cottage, Yewleigh Lane,
 Upton upon Severn, WR8 0QW, United
 Kingdom
 I, Peter Hylands, residing at _____, do declare:

I. I currently hold the position of Research Director at Oxford Natural Products plc
 where I have been employed since April 1999. The research data included in this declaration

NY02-423983.2

was obtained in a barter swap between Oxford Natural Products plc and Proteome Sciences plc, the parent company of the assignee of this application Proteome Sciences Inc, whereby Oxford Natural Products plc carried out work for Proteome Sciences plc during which the data included in this declaration was obtained, in exchange for work carried out by Proteome Sciences plc for

Oxford Natural Products plc in the field of proteomes. Experiments described herein were performed under my supervision as Chief Scientist at Department of Pharmacy, King's College London. A copy of my Curriculum Vitae is attached herewith as Exhibit A.

2. I have read the above-identified application and it is my understanding that the invention disclosed in the above-identified application relates to extracts isolated from *Aristolochia talisman*, methods of using the extracts, compounds isolated from the extracts and methods of using the compounds. The extracts are useful as agents to inhibit mutagenesis, fungal growth, and inflammation.

3. Inflammation is the local accumulation of fluid, plasma proteins, and white blood cells that may result from physical injury, infection, or a local immune response. While acute inflammation relates to early and transient conditions, chronic inflammation is associated with persistent infections, and chronic diseases, such as inflammatory bowel disease, rheumatoid arthritis, synovitis, and psoriasis.

4. Stimulation of the inflammatory response results in arachidonic acid metabolism generated via the lipoxygenase (LOX) and cyclooxygenase (COX) pathways. Stimulation of the LOX pathway can be detected by measuring the formation of leukotrienes, such as leukotriene B₄ (LTB₄), which exhibit proinflammatory activity. Stimulation of the COX pathway can be

detected by measuring prostaglandins, such as prostanglandin E₂ (PGE₂), and thromboxane B₂ (TXB₄), which also induce inflammation.

5. Experiments were conducted to evaluate the effectiveness of extracts isolated from *Aristolochia taliscana* and compounds found therein on the inflammatory response. Specifically, the ability of eupomatenoid compounds derived from *Aristolochia taliscana* extracts were tested for their ability to inhibit the production of LTB₄, PGE₂ and TXB₄.

6. Dried samples of *A. taliscana* leaves were first extracted by maceration for 4 x 48 hours in 3-5 volumes of petroleum ether. Successive extracts were decanted after each 48-hour period, evaporated to dryness and combined. Exhibit B shows the scheme for the identification and isolation of eupomatenoid-1, eupomatenoid-7, eupomatenoid-8 and licarin A by successive chromatographic separations from *A. taliscana* extracts. Initially, the separations were characterized, and their fidelity confirmed using small batches of dried *A. taliscana* approximately 20g. The isolation of eupomatenoid-7 batch sizes of 1-1.5kg were required during scale up procedures.

7. Fractions containing single compounds were evaporated to dryness and the compound re-crystallized from hexane. All columns were packed with chromatographic grade silica, and had dimensions appropriate to the scale of the quantity of crude extract. Elution under gravity was performed with the following solvent systems. (volumes appropriate to scale):

Column 1:light petroleum (br 40°-60°)/CHCl₃ 70/30, 65/35/ 50/50. 30/70; CHCl₃ 100%; CHCl₃/CH₃OH 80/20, 50/50. Column 2: light petroleum/CHCl₃ 80/20, 70/30, 50/50. Column 3: NY02:423983.2

light petroleum/CHCl₃ 70/30, 50/50. Column 4: Hexane/CHCl₃ 2/1. Column 5: Hexane/CHCl₃ 60/40. Column 6: Hexane/CHCl₃ 60/40. Column 7: Hexane/CHCl₃ 2/1.

8. Eupomatenoids-1 and -7 (E1, E7) were analyzed by Time-of-Flight Mass Spectroscopy (TOF-MS) and proton Nuclear Magnetic Resonance Spectroscopy (NMR) and compared to pure compounds to confirm their identities. The authentic compounds were used as reference standards to guide the isolation of those two constituents from the extract using thin-layer chromatography (mobile phase chloroform:hexane 8:3 v/v; development with anisaldehyde reagent and visualization under UV light at 254nm). Purification of sufficient quantities of E7 required scaling up of the extraction/isolation process, and combining final chromatographic fractions.

9. The identities of eupomatenoid-8 (E8) and licarin A were also confirmed by rigorous analysis by TOF-MS and NMR, before the compounds were submitted for biological testing.

10. Exhibit C shows the chemical structures of the isolated eupomatenoid compounds.

11. The effects of the isolated eupomatenoid compounds on inflammation were determined by measuring the generation of prostaglandin E₂ (PGE₂) and thromboxane B₂ (TXB₂) for the divergent COX pathway, or leukotriene B₄ (LTB₄) for the LOX pathway using an *in vitro* rat leukocyte cell model.

12. Mixed leukocytes were obtained from female Wistar rats treated 16 hours previously with 10ml 6% oyster glycogen by peritoneal lavage. The leukocytes were resuspended at 2.5 x 10⁶ cells/ml in Hanks Buffered Saline Solution at 37°C. The cells were then incubated for 5 minutes with each test compound (added in 2µl of DMSO, at final concentrations of 5, 10, 25 or 50 µM).

50 μ g/ml, n=3) prior to challenge with the calcium ionophore, A23187, for 10 min. The cells were pelleted down and the levels of PGE₂, TXB₂ and LTB₄ were measured in the supernatant.

13. The addition of the calcium ionophore A23187 to the mixed leukocyte suspensions produced a robust response, with PGE₂ formation stimulated approximately 6-fold (Exhibit D), TXB₂ generation stimulated 30-fold (Exhibit E), and LTB₄ generation stimulated 40-fold (Exhibit F).

14. Exhibit E shows that E1 inhibited the generation of TXB₂ by approximately 80% at concentration of 5, 10, 25 or 50 μ g/ml (Exhibit E). The formation of PGE₂ was also inhibited, although the effect was not as consistent (Exhibit D). LTB₄ generation did not appear to be inhibited by E1 (Exhibit F). The results with E1 demonstrate that E1 is capable of inhibiting the COX pathway and less effective at inhibiting the LOX pathway.

15. E7 produced a profound inhibition of TXB₂ formation (Exhibit E) and similarly reduced the generation of PGE₂ (Exhibit D). The effect was not restricted to the COX pathway, as a strong inhibitory effect was also seen against LTB₄ generation (Exhibit F).

16. When tested, E8 did not appear to inhibit TXB₂ generation (Exhibit E) and had little or no effect on the formation of PGE₂ (Exhibit D) or LTB₄ (Exhibit F), except at the highest concentration.

17. Like E7, licarin A had a general effect to inhibit A23187-initiated stimulation of TXB₂ and LTB₄, and a reduced generation of PGE₂ (Exhibit D, E, F).

18. Any potential for cytotoxicity was assessed by measurement of changes in the activities of myeloperoxidase (MPO) and lactate dehydrogenase (LDH) enzymes.

19. Supernatants from A23187-treated cells were tested for MPO enzyme activity. Such enzyme activity was detectable by measuring the conversion of the substrate hydrogen peroxide (H_2O_2) to hypochlorous acid (HOCl). Total cellular content of MPO was measured after lysis by the detergent Triton X-100.

20. Cytotoxicity was also assessed by measurement of LDH activity in the supernatant following a fifteen-minute pretreatment with the test compounds. Enzyme activity was measured indirectly by the specific absorption at 340nm of reduced NADH. Triton X-100 was used to solubilize cells, to provide a measurement of total cellular LDH content.

21. The appearance of MPO activity in the medium was increased almost 8-fold above the basal levels in unstimulated cells within 5 minutes of exposure to A23187, and more than 10-fold by ten minutes. Exhibit G and H show that the addition of Triton X-100 produced a maximal release of approximately 18-fold within 5 minutes. Exhibit I shows that the release of LDH was increased more than 4-fold by the addition of A23187 and approached 8-fold when Triton X-100 was added.

22. The MPO release was unaffected by EI at 50 μ g/ml (Exhibit G), although there was a slight elevation of the level of LDH at this concentration (Exhibit I). Thus, EI has little or no cytotoxic effects on the cells.

23. Using the MPO assay, E7 at 50 μ g/ml produced a stimulation of MPO release beyond that obtained by A23187, almost to the extent achieved by cell lysis with the detergent (Exhibit G), suggesting a powerful cytotoxic effect. A similar response seen at 10 and 25 μ g/ml (Exhibit H). The E7 cytotoxic effect was also observed in the LDH assay at all concentrations above 5 μ g/ml (Exhibit I).

24. Using the MPO assay, E8 appeared to abolish MPO release and/or activity at 10, 25 and 50 μ g/ml (Exhibit G and H). The mechanism responsible for the inhibition of MPO release and/or activity is not clear, but may reflect a general cytoprotective property of the compound since there was also a small inhibition of LDH release (Exhibit I). Alternatively, E8 may be able to scavenge the substrate hydrogen peroxide, or inhibit the MPO enzyme.

25. MPO release was increased by licarin A (Exhibit G) and reflected in the measurements of LDH release (Exhibit I). Thus, licarin A exhibits a strong cytotoxic effect.

26. These results demonstrate that E1 is a selective inhibitor of the COX pathway, with little or no propensity for cytotoxicity and thus acts as a potent inhibitor of the inflammatory response. Although E8 appears to be a weak inhibitor of LTB₄, PGE₂ and TXB₄ production, the compound does seem to have some cytoprotective properties. Although E7 and licarin A exhibit some cytotoxic effects, these compounds are capable of inhibiting the formation of the LTB₄, PGE₂ and TXB₄ and have potential for use as inhibitors of the inflammatory response. Table 1 summarizes the results of the experiments presented herein.

A32964-072874.0132

27. I hereby declare that all statements made herein by my own knowledge are true, and that all statements made on information and belief are believed to be true, and further that I make these statements with the knowledge that willful false statements, and the like, are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of any patent issuing from the above-identified application.

Dated: 4 March 2003

Signature: 

Table 1. The effects of eupomatenoids on inflammatory cell biomarkers

Compound	PGE ₂	TXB ₂	LTB ₂	MPO ₁	LDH ₂
Eupomatenoid 1	+	+	-	0	+/-
Eupomatenoid 7	+	+	+	+	+
Eupomatenoid 8	+/-	0	+/-	-	-
Licarin A	+/-	+	+	+	+

"+" indicates activity against the target, "+/—" indicates weak anti-inflammatory or cytotoxic activity, "0" indicates no effect, and "-" indicates an inhibitory action.

Peter J Hylands, PhD

Professor Hylands is a pharmaceutical chemist and started his career with academic appointments in the University of Strasbourg as a Royal Society European fellow from 1970-1972 followed by 15 years in the University of London. His special research interest has always been the use of plants in medicine. He joined the commercial world in 1988 as Director of Chemistry at Xenova Limited and then as Research Director of PHYTOpharmaceuticals, Incorporated (USA), both of which were dedicated to the discovery and commercialization of pharmaceuticals derived from natural products. He has acted as a consultant for the United Nations and Commonwealth Science Council. He has worked with European and US-based companies and institutions and is well connected in every continent with regard to natural product research and development. He also serves on a number of boards and advisory boards and as a Visiting Professor in the Department of Pharmacy, King's College London. He cofounded Oxford Natural Products plc in 1998 and serves as the company's Chief Scientific Officer.






Exhibit B

Scheme for the chromatographic isolations of the compounds eupomatenoid-1 (E1), eupomatenoid-7 (E7), eupomatenoid-8 (E8) and licarin A (LA) from the petroleum-ether extract of *A. taliscana* leaf.


Exhibit C Structures of eupomatenoids from *A. taliscana*




Eupomatenoid-1



Eupomatenoid-7



Eupomatenoid-8



Licanin A




Exhibit D

Effect of eupomatenoid compounds at 5, 10, 25 or 50 µg/ml on the stimulation by A23187 of PGE₂ formation in rat leukocytes




Exhibit E

Effect of eupomatenoid compounds at 5, 10, 25 or 50 µg/ml on the stimulation by A23187 of TBX₂ formation in rat leukocytes




Exhibit F

**Effect of eupomatenoid compounds at 5, 10, 25 or 50 µg/ml on
The stimulation by A23187 of LTB₄ formation in rat leukocytes**




Exhibit G

Effect of eupomatenoid compounds at 50 μ g/ml on the release of myeloperoxidase from rat leukocytes




Exhibit H

Stimulation by E7 and inhibition by E8 at 10, 25 or 50 μ g/ml of release or activity of MPO in rat leukocytes




Exhibit I

Effect of eupomatenoid compounds at 5-50 μ g/ml on release of LDH from rat leukocytes